M D Marcus1, D E Wilfley2, L El Ghormli3, P Zeitler4, B Linder5, K Hirst3, C E Ievers-Landis6, D J van Buren2, N Walders-Abramson4. 1. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA. 2. Department of Psychiatry, Washington University School of Medicine, St Louis, MO. 3. George Washington University, Biostatistics Center, Rockville, MD. 4. Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, CO. 5. Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 6. Rainbow Babies and Children's Hospital, University Hospitals Case Medical Center, Cleveland, OH.
Abstract
BACKGROUND: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial documented that metformin plus rosiglitazone, but not metformin plus lifestyle intervention, provided superior durability of glycemic control relative to metformin monotherapy. OBJECTIVES: We examined weight changes among TODAY participants that completed at least 6 months of treatment, evaluated predictors of lifestyle outcome, and examined whether weight changes were related to cardiometabolic outcomes across treatment arms. METHODS: The 595 youth with type 2 diabetes, (85.1% of randomized participants aged 11-17 years) completed assessments of weight-related and cardiometabolic measures at months 0, 6, 12 and 24. Repeated measures models were used to investigate associations over time. RESULTS: Lifestyle intervention did not enhance outcome relative to metformin alone and no predictors of response to lifestyle treatment were identified. However, changes in percent overweight across treatment arms were associated with changes in multiple cardiometabolic risk factors, and decreases of ≥ 7% in overweight were associated with significant benefits over 24 months. CONCLUSIONS: Although adjunctive intensive lifestyle intervention did not improve weight-related outcomes, weight changes in the full TODAY sample were associated with small, but significant improvements in cardiometabolic status, highlighting the importance of optimizing weight management in youth with T2DM.
RCT Entities:
BACKGROUND: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) clinical trial documented that metformin plus rosiglitazone, but not metformin plus lifestyle intervention, provided superior durability of glycemic control relative to metformin monotherapy. OBJECTIVES: We examined weight changes among TODAY participants that completed at least 6 months of treatment, evaluated predictors of lifestyle outcome, and examined whether weight changes were related to cardiometabolic outcomes across treatment arms. METHODS: The 595 youth with type 2 diabetes, (85.1% of randomized participants aged 11-17 years) completed assessments of weight-related and cardiometabolic measures at months 0, 6, 12 and 24. Repeated measures models were used to investigate associations over time. RESULTS: Lifestyle intervention did not enhance outcome relative to metformin alone and no predictors of response to lifestyle treatment were identified. However, changes in percent overweight across treatment arms were associated with changes in multiple cardiometabolic risk factors, and decreases of ≥ 7% in overweight were associated with significant benefits over 24 months. CONCLUSIONS: Although adjunctive intensive lifestyle intervention did not improve weight-related outcomes, weight changes in the full TODAY sample were associated with small, but significant improvements in cardiometabolic status, highlighting the importance of optimizing weight management in youth with T2DM.
Authors: Katherine M Flegal; Rong Wei; Cynthia L Ogden; David S Freedman; Clifford L Johnson; Lester R Curtin Journal: Am J Clin Nutr Date: 2009-09-23 Impact factor: 7.045
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Melissa A Kalarchian; Michele D Levine; Silva A Arslanian; Linda J Ewing; Patricia R Houck; Yu Cheng; Rebecca M Ringham; Carrie A Sheets; Marsha D Marcus Journal: Pediatrics Date: 2009-09-28 Impact factor: 7.124
Authors: Mary Savoye; Melissa Shaw; James Dziura; William V Tamborlane; Paulina Rose; Cindy Guandalini; Rachel Goldberg-Gell; Tania S Burgert; Anna M G Cali; Ram Weiss; Sonia Caprio Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: D Kendall; A Vail; R Amin; T Barrett; P Dimitri; F Ivison; M Kibirige; V Mathew; K Matyka; A McGovern; H Stirling; L Tetlow; J Wales; N Wright; P Clayton; C Hall Journal: J Clin Endocrinol Metab Date: 2012-11-21 Impact factor: 5.958
Authors: Maria I Constantino; Lynda Molyneaux; Franziska Limacher-Gisler; Abdulghani Al-Saeed; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2013-07-11 Impact factor: 19.112
Authors: Robert I Berkowitz; Marsha D Marcus; Barbara J Anderson; Linda Delahanty; Nisha Grover; Andrea Kriska; Lori Laffel; Amy Syme; Elizabeth Venditti; Dorothy J Van Buren; Denise E Wilfley; Patrice Yasuda; Kathryn Hirst Journal: Pediatr Diabetes Date: 2017-06-30 Impact factor: 4.866
Authors: Jana L Slaght; Brandy Alexandra Wicklow; Allison B Dart; Elizabeth A C Sellers; Melissa Gabbs; Marylin Carino; Jonathan M McGavock Journal: BMJ Open Diabetes Res Care Date: 2021-05
Authors: Silva Arslanian; Fida Bacha; Margaret Grey; Marsha D Marcus; Neil H White; Philip Zeitler Journal: Diabetes Care Date: 2018-12 Impact factor: 19.112
Authors: Alaina P Vidmar; Monica Naguib; Jennifer K Raymond; Sarah Jeanne Salvy; Elizabeth Hegedus; Choo Phei Wee; Michael I Goran Journal: Nutrients Date: 2021-10-21 Impact factor: 5.717